{"id":558820,"date":"2026-11-04T10:44:28","date_gmt":"2026-11-04T10:44:28","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/558820\/gastroenteropancreatic-neuroendocrine-tumors-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight.html"},"modified":"2026-11-04T10:44:28","modified_gmt":"2026-11-04T10:44:28","slug":"gastroenteropancreatic-neuroendocrine-tumors-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight","status":"publish","type":"post","link":"http:\/\/www.northcarolinaheadlines.com\/news\/story\/558820\/gastroenteropancreatic-neuroendocrine-tumors-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight.html","title":{"rendered":"Gastroenteropancreatic Neuroendocrine Tumors Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/11\/1793805963.jpg\" style=\"border:none !important\" target=\"_blank\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-medium wp-image-29\" title=\"Gastroenteropancreatic Neuroendocrine Tumors Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/11\/1793805963.jpg\" alt=\"Gastroenteropancreatic Neuroendocrine Tumors Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The Key GEP-NET Companies in the market include \u2013 Novartis, Pfizer, Exelixis, Ipsen Biopharmaceuticals, ITM Isotope Technologies Munich, Camurus AB, Bristol Myers Squibb, RayzeBio, and others.<\/div>\n<p style=\"text-align: justify\">(Albany, US), November 04, 2026 &#8211; DelveInsight&#8217;s &#8216;Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Insights, Epidemiology and Market Forecast &ndash; 2036&#8217; report delivers an in-depth understanding of Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology, as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\"><strong>Explore the intricate details of the Gastroenteropancreatic Neuroendocrine Tumors Market Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Gastroenteropancreatic Neuroendocrine Tumors Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Key Takeaways from the Gastroenteropancreatic Neuroendocrine Tumors Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">According to Camurus AB&rsquo;s 2026 presentation, results from the Phase III SORENTO trial are anticipated to be presented in 2026.<\/p>\n<\/li>\n<li>\n<p>The GEP-NET market is anticipated to grow at a significant CAGR during the forecast period of 2026-2036.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&#8217;s analysis, the US contributed the highest number of incident cases of NETs, with total incident cases of NETs in the United States in 2025 being 31,000.<\/p>\n<\/li>\n<li>\n<p>GEP-NETs represent the most common NET subtype, comprising 50&ndash;70% of all NETs.<\/p>\n<\/li>\n<li>\n<p>A significant proportion of GEP NET express somatostatin receptors, particularly in well and moderately differentiated tumors, which underpins the use of somatostatin analogs and peptide receptor radionuclide therapies.<\/p>\n<\/li>\n<li>\n<p>Despite advances in diagnostics, GEP-NET are often not identified for up to 5&ndash;7 years after clinical symptoms appear, as the symptoms are not specific.<\/p>\n<\/li>\n<li>\n<p>Radiomedix and Orano Med are developing AlphaMedix, the first radioligand therapy to receive BTD, which has demonstrated a response rate of 62.5% in GEP-NET patients who had not previously undergone PRRT with LUTATHERA.<\/p>\n<\/li>\n<li>\n<p>The development of innovative therapies, particularly radioligand treatments and alpha emitter-based therapies, is driving growth in the Gastroenteropancreatic Neuroendocrine Tumors market, while manufacturing and administration challenges and generic competition remain barriers.<\/p>\n<\/li>\n<li>\n<p>The leading GEP-NET companies include Novartis, Pfizer, Exelixis, Ipsen Biopharmaceuticals, ITM Isotope Technologies Munich, Camurus AB, Bristol Myers Squibb, RayzeBio, and others.<\/p>\n<\/li>\n<li>\n<p>Promising GEP-NET therapies include LUTATHERA (lutetium Lu 177 DOTATATE), SOMATULINE DEPOT (Lanreotide), ZANOSAR (Streptozocin), ITM-11 (n.c.a. 177Lu-edotreotide), CAM2029, RYZ101, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Get a Free sample for the Gastroenteropancreatic Neuroendocrine Tumors Market Forecast, Size &amp; Share Analysis Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">GEP-NET Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Gastroenteropancreatic Neuroendocrine Tumors Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) are rare, heterogeneous cancers arising from neuroendocrine cells in the gastrointestinal tract and pancreas. Their complexity and late-stage presentation require individualized treatment based on tumor grade, location, hormone activity, and patient symptoms, with management primarily focused on advanced and metastatic disease. Incidence has increased over recent decades, partly due to enhanced detection and imaging practices, although exact rates vary by region and subtype. Diagnosis of GEP NET relies on a combination of biochemical testing, imaging, and sometimes genetic evaluation. Common biochemical markers include chromogranin A, pancreatic hormones (insulin, gastrin, glucagon), and serotonin metabolites such as 5-HIAA in urine, depending on tumor functionality. Imaging studies such as contrast-enhanced CT and MRI are used to localize primary tumors and assess metastatic spread.<\/p>\n<p style=\"text-align: justify\"><strong>Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Segmentation in the 7MM<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Incident Cases of NET<\/p>\n<\/li>\n<li>\n<p>Total Incident Cases of GEP-NET<\/p>\n<\/li>\n<li>\n<p>Grade-specific Incident Cases of GEP-NET<\/p>\n<\/li>\n<li>\n<p>Functional status Incident Cases of GEP-NET<\/p>\n<\/li>\n<li>\n<p>Stage-specific Incident Cases of GEP-NET<\/p>\n<\/li>\n<li>\n<p>SSR Positive Incident Cases of GEP-NET<\/p>\n<\/li>\n<li>\n<p>Total Treated Cases of GEP-NET<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Download the report to understand which factors are driving Gastroenteropancreatic Neuroendocrine Tumors Epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">GEP-NET Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Key Findings<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>The US contributed to the highest incident cases of NETs. The total incident cases of NETs in the United States in 2025 were 31,000.<\/p>\n<\/li>\n<li>\n<p>According to secondary research, the incidence of malignant GEP-NET during 2000&ndash;2007 was 1.7 per 100,000 population per year in Europe, corresponding to an estimated 26,000 new cases.<\/p>\n<\/li>\n<li>\n<p>In Spain, the annual incidence of the disease was 6.47 cases per 100,000 population, with an adjusted prevalence of 0.052%. The mean age at diagnosis was 58 &plusmn; 15 years, and the gender distribution was nearly equal, with 51% men and 49% women.<\/p>\n<\/li>\n<li>\n<p>Surgical resection of the primary tumor was performed in 66% of patients. Histopathological grading showed that most tumors were well differentiated, with 73% classified as Grade 1 (G1), 22% as Grade 2 (G2), and 5% as Grade 3 (G3).<\/p>\n<\/li>\n<li>\n<p>The most common primary tumor site was the pancreas (52%), followed by the jejunum&ndash;ileum (23%). At the time of diagnosis, 24% of patients presented with distant metastases, most frequently involving the liver (44%), peritoneum (25%), or multiple organs (22%). The majority of tumors were sporadic and non-functional.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Approved Therapies for Gastroenteropancreatic Neuroendocrine Tumors<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>LUTATHERA (lutetium Lu 177 DOTATATE): Novartis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">LUTATHERA is indicated for adult patients with somatostatin receptor-positive GEP-NET. In September 2017, the EMA approved LUTATHERA for the treatment of GEP-NET, the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NET. LUTATHERA has demonstrated meaningful progression-free survival benefits, and it is also approved for supply in Australia, listed on the Australian Register of Therapeutic Goods (ARTG) under ARTG number 455452, with a registration date of November 2025.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">SOMATULINE DEPOT is a SSA indicated for the treatment of adult patients with unresectable well or moderately differentiated, locally advanced, or metastatic GEP-NET to improve progression-free survival. The drug is also approved for the treatment of adults with carcinoid syndrome by reducing the frequency of short-acting SSA rescue therapy. It is administered subcutaneously.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>ZANOSAR (Streptozocin): Pfizer<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">ZANOSAR is a small molecule alkylating anti-tumor antibiotic administered by IV infusion, approved for PNET\/GEP-NET (US: 1982 for PNET; JP: 2014 for GEP-NET).<\/p>\n<p style=\"text-align: justify\"><strong>Discover more about therapies set to grab Major Gastroenteropancreatic Neuroendocrine Tumors Market Share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">GEP-NET Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Gastroenteropancreatic Neuroendocrine Tumors Pipeline Analysis<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>ITM-11 (n.c.a. 177Lu-edotreotide): ITM Isotope Technologies Munich<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">ITM-11 is an innovative targeted radionuclide therapy agent being developed by ITM Isotope Technologies Munich. It is currently being investigated in two Phase III clinical trials, COMPETE (GEP-NET G1\/G2) and COMPOSE (well-differentiated high Grade 2 and Grade 3 GEP-NET). In November 2025, ITM announced that the FDA completed its filing review and accepted the company&#8217;s New Drug Application for 177Lu-edotreotide, with a PDUFA goal date of August 28, 2026.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>CAM2029: Camurus AB<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">CAM2029 is a ready-to-use, long-acting, subcutaneous depot of octreotide being developed by Camurus AB. Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and exposure compared to current market-leading products, and it is designed to enable easy self-administration, including the option of a pre-filled pen device. The drug is being evaluated in the Phase III SORENTO study in patients with GEP-NET, with PFS readout data anticipated in mid to late 2026.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>RYZ101: RayzeBio<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">RYZ101 is an emerging radioligand therapy designed to deliver targeted alpha radiation to somatostatin receptor&ndash;expressing tumors, currently in Phase III for SSTR+ GEP-NET.<\/p>\n<p style=\"text-align: justify\"><strong>Gastroenteropancreatic Neuroendocrine Tumors Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify\">The Gastroenteropancreatic Neuroendocrine Tumors market is undergoing a steady shift as deeper insights into tumor biology and receptor expression patterns reshape treatment approaches. GEP NET management is now benefiting from advances in targeted pathways, including mTOR inhibition and somatostatin receptor directed strategies, which are improving disease stabilization and delaying progression, particularly in patients with well-differentiated tumors. At the same time, radioligand-based therapies continue to evolve, with ongoing refinements in peptide receptor targeting and radionuclide design, as seen with agents such as LUTATHERA and Iodine-131 metaiodobenzylguanidine (131I-MIBG). The clinical pipeline is expanding with novel agents, including next-generation receptor-targeted compounds, angiogenesis inhibitors such as sunitinib, and combination regimens designed to address resistance and tumor heterogeneity. Improvements in functional imaging, including Ga-68 DOTATATE PET\/CT, and biomarker research are also enabling more accurate disease monitoring and treatment selection. Overall, growing clinical interest, increasing diagnosis rates, and continued innovation in targeted and radioligand therapies are expected to support sustained growth across major regions, while emerging candidates such as surufatinib and 177Lu-edotreotide are anticipated to increase competition.<\/p>\n<p style=\"text-align: justify\"><strong>Gastroenteropancreatic Neuroendocrine Tumors Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Increasing incidence and improved diagnosis<\/p>\n<\/li>\n<li>\n<p>Advancements in targeted and radioligand therapies<\/p>\n<\/li>\n<li>\n<p>Expanding research and clinical pipeline<\/p>\n<\/li>\n<li>\n<p>Rising awareness and early detection programs<\/p>\n<\/li>\n<li>\n<p>Favorable regulatory support for rare cancers, including orphan drug incentives, accelerated approvals, and supportive reimbursement policies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Gastroenteropancreatic Neuroendocrine Tumors Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Complex nature of GEP-NET<\/p>\n<\/li>\n<li>\n<p>Challenges in drug manufacturing and administration<\/p>\n<\/li>\n<li>\n<p>Impact of generic competition on the sales of approved drugs<\/p>\n<\/li>\n<li>\n<p>Diagnostic delays, as symptoms are not specific<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Gastroenteropancreatic Neuroendocrine Tumors Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify\">Surgery, the only curative treatment for GEP-NET, is generally considered a first-line treatment for localized NETs. For advanced, metastatic, or unresectable disease, treatment options include peptide receptor radionuclide therapy (PRRT) with LUTATHERA, somatostatin analogs such as octreotide and lanreotide to control hormone-related symptoms and tumor growth, targeted therapies like everolimus and sunitinib for pancreatic NETs, and cytotoxic chemotherapy (temozolomide or capecitabine-based regimens) for high-grade tumors. Key unmet needs include diagnostic delays and disease presentation, treatment resistance and disease progression, resistance to standard therapies, and gaps in long-term disease management.<\/p>\n<p style=\"text-align: justify\"><strong>To know more about GEP-NET Companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Will Insurance Cover PRRT for GEP-NET?<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Scope of the Gastroenteropancreatic Neuroendocrine Tumors Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Coverage- 7MM<\/p>\n<\/li>\n<li>\n<p>Study Period- 2022-2036<\/p>\n<\/li>\n<li>\n<p>Forecast Period- 2026-2036<\/p>\n<\/li>\n<li>\n<p>Gastroenteropancreatic Neuroendocrine Tumors Companies- Novartis, Pfizer, Exelixis, Ipsen Biopharmaceuticals, ITM Isotope Technologies Munich, Camurus AB, Bristol Myers Squibb, RayzeBio, and others.<\/p>\n<\/li>\n<li>\n<p>Gastroenteropancreatic Neuroendocrine Tumors Therapies- LUTATHERA (lutetium Lu 177 DOTATATE), SOMATULINE DEPOT (Lanreotide), ZANOSAR (Streptozocin), ITM-11 (n.c.a. 177Lu-edotreotide), CAM2029, RYZ101, and others.<\/p>\n<\/li>\n<li>\n<p>Gastroenteropancreatic Neuroendocrine Tumors Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumors market drivers and market barriers<\/p>\n<\/li>\n<li>\n<p>Gastroenteropancreatic Neuroendocrine Tumors Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis<\/p>\n<\/li>\n<li>\n<p>Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs, KOL Views, Reimbursement<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Market Methodology of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)<\/p>\n<\/li>\n<li>\n<p>Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)<\/p>\n<\/li>\n<li>\n<p>Patient Journey of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)<\/p>\n<\/li>\n<li>\n<p>Marketed Therapies<\/p>\n<\/li>\n<li>\n<p>Emerging Therapies<\/p>\n<\/li>\n<li>\n<p>Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Seven Major Market Analysis<\/p>\n<\/li>\n<li>\n<p>Unmet Needs of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)<\/p>\n<\/li>\n<li>\n<p>KOL Views of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ol>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Abhishek kumar<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gastroenteropancreatic-neuroendocrine-tumors-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gastroenteropancreatic-neuroendocrine-tumors-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key GEP-NET Companies in the market include \u2013 Novartis, Pfizer, Exelixis, Ipsen Biopharmaceuticals, ITM Isotope Technologies Munich, Camurus AB, Bristol Myers Squibb, RayzeBio, and others. (Albany, US), November 04,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/558820"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=558820"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/558820\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=558820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=558820"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=558820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}